We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+4.83%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$46B
AUM Growth
+$2.18B
(+5%)
Cap. Flow
+$425M
Cap. Flow
% of AUM
0.92%
Top 10 Holdings %
Top 10 Hldgs %
15.17%
Holding
2,954
New
28
Increased
2,252
Reduced
604
Closed
50
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DuPont de Nemours
DD
|
+$128M |
| 2 |
Baker Hughes
BKR
|
+$26.7M |
| 3 |
IQVIA
IQV
|
+$14.5M |
| 4 |
Oneok
OKE
|
+$14.3M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DD
Du Pont De Nemours E I
DD
|
+$114M |
| 2 |
RAI
Reynolds American Inc
RAI
|
+$88.6M |
| 3 |
BHI
Baker Hughes
BHI
|
+$41.6M |
| 4 |
WFM
Whole Foods Market Inc
WFM
|
+$26.7M |
| 5 |
UnitedHealth
UNH
|
+$22.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.64% |
| 2 | Technology | 15.8% |
| 3 | Healthcare | 13.57% |
| 4 | Industrials | 10.87% |
| 5 | Consumer Discretionary | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2301
Abeona Therapeutics
ABEO
$366M
| $505K | ﹤0.01% |
1,186
+1
| +0.1% | +$269 |
|
2302
Unisys
UIS
$209M
| $503K | ﹤0.01% |
59,158
-513
| -0.9% | -$4.97K |
|
2303
Live Oak Bancshares
LOB
$1.98B
| $502K | ﹤0.01% |
21,389
+395
| +2% | +$9.23K |
|
2304
BioCryst Pharmaceuticals
BCRX
$2.28B
| $500K | ﹤0.01% |
95,458
+1,155
| +1% | +$5.91K |
|
2305
NACCO Industries
NC
$357M
| $500K | ﹤0.01% |
25,500
+131
| +0.5% | +$2.17K |
|
2306
Inovio Pharmaceuticals
INO
$55.7M
| $498K | ﹤0.01% |
6,552
+111
| +2% | +$8.26K |
|
2307
Park-Ohio Holdings
PKOH
$575M
| $498K | ﹤0.01% |
10,921
+90
| +0.8% | +$3.61K |
|
|
EVBG
2308
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $498K | ﹤0.01% |
18,841
+270
| +1% | +$6.32K |
|
2309
Iovance Biotherapeutics
IOVA
$1.82B
| $497K | ﹤0.01% |
64,065
+365
| +0.6% | +$2.31K |
|
2310
York Water
YORW
$502M
| $496K | ﹤0.01% |
14,637
+412
| +3% | +$14K |
|
|
HZN
2311
DELISTED
Horizon Global Corporation
HZN
| $495K | ﹤0.01% |
28,065
+375
| +1% | +$6.11K |
|
2312
Barrett Business Services
BBSI
$959M
| $493K | ﹤0.01% |
34,880
+440
| +1% | +$5.95K |
|
2313
CVR Energy
CVI
$3.58B
| $493K | ﹤0.01% |
19,046
+165
| +0.9% | +$3.51K |
|
|
ALTA
2314
DELISTED
Altabancorp
ALTA
| $490K | ﹤0.01% |
15,096
+55
| +0.4% | +$1.53K |
|
2315
PDF Solutions
PDFS
$1.93B
| $488K | ﹤0.01% |
31,517
+420
| +1% | +$6.77K |
|
|
NETI
2316
DELISTED
Eneti Inc.
NETI
| $487K | ﹤0.01% |
7,425
+56
| +0.8% | +$3.88K |
|
|
ATRS
2317
DELISTED
Antares Pharma, Inc.
ATRS
| $487K | ﹤0.01% |
150,288
+3,363
| +2% | +$10.4K |
|
|
KDNY
2318
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $485K | ﹤0.01% |
9,106
+128
| +1% | +$7.61K |
|
2319
Kopin
KOPN
$652M
| $484K | ﹤0.01% |
116,150
+2,110
| +2% | +$8.27K |
|
|
FRBK
2320
DELISTED
Republic First Bancorp Inc
FRBK
| $482K | ﹤0.01% |
52,128
+390
| +0.8% | +$3.47K |
|
2321
Geospace Technologies
GEOS
$94.6M
| $481K | ﹤0.01% |
27,003
+560
| +2% | +$8.52K |
|
2322
The Bancorp
TBBK
$2.79B
| $481K | ﹤0.01% |
58,165
+440
| +0.8% | +$3.41K |
|
2323
CNB Financial Corp
CCNE
$1.04B
| $480K | ﹤0.01% |
17,584
+178
| +1% | +$4.48K |
|
|
VWTR
2324
DELISTED
Vidler Water Resouces, Inc. Common Stock
VWTR
| $479K | ﹤0.01% |
28,693
+325
| +1% | +$5.4K |
|
2325
Seneca Foods Class A
SENEA
$1.12B
| $478K | ﹤0.01% |
13,867
+530
| +4% | +$15.7K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2017 Portfolio in Review
As of Q3 2017, RhumbLine Advisers held 2,954 positions worth $46B, up 5% from $43.8B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Trading was light in Q3 2017: portfolio turnover was 2.6%. RhumbLine Advisers opened 28 new positions and exited 50, leaving the 2,954-position portfolio largely intact.
By sector, the portfolio is most concentrated in Financials at 17% of assets, up from 16% a quarter earlier, followed by Technology and Healthcare.
- RhumbLine Advisers's largest Q3 2017 buy was Baker Hughes: 750,985 shares worth $27.5M.
- RhumbLine Advisers added most to DuPont de Nemours in Q3 2017, an estimated $128M increase.
- RhumbLine Advisers's biggest Q3 2017 reduction was UnitedHealth, cutting an estimated $22.8M.
- RhumbLine Advisers fully exited Du Pont De Nemours E I in Q3 2017, selling an estimated $114M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $46B portfolio in Q3 2017.
- RhumbLine Advisers opened 28 new positions and closed 50 in Q3 2017.
- RhumbLine Advisers's portfolio value rose 5% quarter-over-quarter to $46B.
Based on RhumbLine Advisers's 13F filing for Q3 2017, filed 6 Nov 2017.